CN109694895A - 松花活性肽、包含其的组合物、木耳片及其制备工艺 - Google Patents
松花活性肽、包含其的组合物、木耳片及其制备工艺 Download PDFInfo
- Publication number
- CN109694895A CN109694895A CN201910168836.5A CN201910168836A CN109694895A CN 109694895 A CN109694895 A CN 109694895A CN 201910168836 A CN201910168836 A CN 201910168836A CN 109694895 A CN109694895 A CN 109694895A
- Authority
- CN
- China
- Prior art keywords
- preserved egg
- active peptide
- parts
- agaric
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 25
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 22
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 20
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 20
- 229940111202 pepsin Drugs 0.000 claims abstract description 20
- 241000233866 Fungi Species 0.000 claims abstract description 14
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 12
- 238000009835 boiling Methods 0.000 claims abstract description 12
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000000853 adhesive Substances 0.000 claims abstract description 7
- 230000001070 adhesive effect Effects 0.000 claims abstract description 7
- 230000002829 reductive effect Effects 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 5
- 239000011122 softwood Substances 0.000 claims abstract description 5
- 238000005550 wet granulation Methods 0.000 claims abstract description 5
- 235000020985 whole grains Nutrition 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 46
- 239000000758 substrate Substances 0.000 claims description 41
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 229940088598 enzyme Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 17
- 108091005804 Peptidases Proteins 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 15
- 239000003513 alkali Substances 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 12
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 8
- 230000001376 precipitating effect Effects 0.000 claims description 8
- 230000009849 deactivation Effects 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 102000005158 Subtilisins Human genes 0.000 claims description 2
- 108010056079 Subtilisins Proteins 0.000 claims description 2
- 230000003579 anti-obesity Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 claims 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims 1
- 229910001948 sodium oxide Inorganic materials 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 abstract description 9
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 9
- 238000005498 polishing Methods 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 46
- 239000000243 solution Substances 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 102000035195 Peptidases Human genes 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 235000019419 proteases Nutrition 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 8
- 229960001243 orlistat Drugs 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000004367 Lipase Substances 0.000 description 6
- 102000004882 Lipase Human genes 0.000 description 6
- 108090001060 Lipase Proteins 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229940040461 lipase Drugs 0.000 description 6
- 235000019421 lipase Nutrition 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 229940086609 Lipase inhibitor Drugs 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100020720 Calcium channel flower homolog Human genes 0.000 description 3
- 101000932468 Homo sapiens Calcium channel flower homolog Proteins 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 corrigent Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000011871 bio-impedance analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000020339 pu-erh tea Nutrition 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
本发明涉及松花活性肽、包含其的组合物、木耳片及其制备工艺,所述木耳片按重量份包括木香4份;香附4份;干姜4份;决明子4份;黄芪4份;松花活性肽2~8份,黑木耳80份;所述松花活性肽由松花分离蛋白依次经胃蛋白酶和碱性蛋白酶水解所得,所述木耳片的制备方法为:步骤1、将木香、香附、干姜、决明子、黄芪混合均匀后,用水煎煮提取2次,减压浓缩得中药浸膏;步骤2、黑木耳用水浸泡后煮熟,打磨成浆,得木耳浆;步骤3、向木耳浆中加入中药浸膏以及松花活性肽,搅拌均匀后,加入粘合剂,混合均匀,制成软材,然后经湿法制粒、干燥、整粒,压片,即得木耳片。本发明减肥效果显著,且成分天然、无副作用。
Description
技术领域
本发明属于减肥保健品领域,尤其涉及一种松花活性肽、包含其的组合物、木耳片及其制备工艺。
背景技术
随着社会的发展,人民生活水平的提高,肥胖,已经成为普遍现象。肥胖是指一定程度的明显超重与脂肪层过厚,是体内脂肪,尤其是甘油三酯积聚过多而导致的一种状态。
由于食物摄入过多或机体代谢的改变而导致体内脂肪积聚过多造成体重过度增长并引起人体病理、生理改变或潜伏。肥胖有以下危害:1、增加心血管疾病的危险;2、影响消化系统的功能;3、影响内分泌系统的功能;4、增加癌症发生的危险性;5、此外还有关节软组织损伤、生殖能力下降以及心理障碍等。
当前,世界卫生组织己确认肥胖将成为全球首位的健康问题,其成因除与遗传有关外,更与后天代谢异常、饮食因素相关。目前,肥胖已经成为影响人们健康的杀手,减肥成为主流,特别是正处于青春期的女性,减肥,不仅使得身体健康,而且还能够使自己变得漂亮,苗条,有魅力。
目前,常用的减肥方法有:灌肠减肥法、渗透压减肥法、桑拿减肥法、奶粉减肥法、跳绳减肥法、普洱茶减肥法、手术减肥、药物减肥等。但是,对于大多数青春年少的女性来说,运动减肥太累,一般坚持不下来,而喝茶减肥成本又太高,且大多数人没有喝茶的习惯。节食减肥很痛苦,且不科学,对身体非常不利。而药物减肥因为方便、省事备受人们青睐,但是目前市售的减肥产品主要分为两类,1)作用于中枢的减肥产品,2)作用于外周的减肥产品,主要是脂肪酶抑制剂;作用于中枢的减肥产品主要是通过抑制大脑进食中枢达到控制食欲的目的,使食物摄取减少,同时通过增加中枢交感传出神经的兴奋性,来兴奋棕色脂肪β3肾上腺素受体来增加产热,从而达到脂肪的消耗增加的目的;其不良反应较多,容易引发肠功能紊乱,贫血,糖尿病,肾功能损害,或者效果不明显,或者容易反弹,且存在有增加抑郁及焦虑的风险;而作用于外周的脂肪酶抑制剂,代表药物为奥利司他和新利司他,由于其不进入人体血管和神经系统,对人体矿物质平衡以及骨质循环无影响,备受人们喜爱,但是,由于其为化学合成药物,存在潜在的毒副作用,而动物源或植物源活性成分作为脂肪酶抑制剂具有天然、安全、结构多样等特点成为近年来研究的热点。
发明内容
本发明的目的在于克服现有技术的缺陷,提供一种松花活性肽、包含其的组合物、木耳片及其制备工艺。
为了实现上述目的,本发明采取的技术方案如下:
技术方案一:
一种松花活性肽,由松花分离蛋白依次经胃蛋白酶和碱性蛋白酶水解所得,具体步骤如下:
步骤一:酶解:首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用盐酸调整底物溶液的pH为4.2,并加热至37摄氏度后,以底物计向底物溶液中加入1100U/g的胃蛋白酶,于37摄氏度PH4.2的条件下酶解30~60min,然后采用氢氧化钠调整底物溶液的pH为8.0,并升温至54摄氏度后,以底物计向其中加入2606U/g的碱性蛋白酶,于54摄氏度、pH8.0的条件下酶解60~90min,然后沸水浴中灭酶15min;得酶解液;
步骤二:固液分离:将步骤一所得的酶解液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
进一步的,步骤二中,在离心前还包括采用分子量为5kDa和3KDa的超滤膜盒依次对酶解液进行分离,收集分子量在3~5kDa范围内的组分。
技术方案二:
一种权利要求1~2任一项所述松花活性肽作为减肥活性成分在制备减肥药物中的应用。
技术方案三:
一种包含权利要求1~2任一项所述松花活性肽的组合物,包括以下重量份的各原料:木香4份;香附4份;干姜4份;决明子4份;黄芪4份;权利要求1~2任一项所述松花活性肽2~9份。
进一步的,如果采用权利要求1中方法制备的松花活性肽,则松花活性肽为3~9份;
如果采用权利要求2中方法制备的松花活性肽,则松花活性肽为2~6份;
进一步的,所述组合物还包括药学上可接受的载体。例如:填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括:淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等;崩解剂包括:淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素钠等;润滑剂包括:硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等;助悬剂包括:聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等;粘合剂包括,淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等;甜味剂包括:糖精钠、阿斯帕坦、蔗糖、甜蜜素、甘草次酸等;矫味剂包括:甜味剂及各种香精;防腐剂包括:尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等;基质包括:PEG6000,PEG4000,虫蜡等。为使上述剂型能够实现中药药剂学,需在制备这些剂型时加入药学可接受的其它辅料。
技术方案四:
一种包含上述组合物的临床制剂,所述制剂为口服剂型,选自汤剂、散剂、胶囊剂、片剂、合剂、糖浆剂、内服膏剂、丸剂或口服液。
技术方案五:
一种包含上述组合物的木耳片,按重量份计,还包括黑木耳80份。
技术方案六:
一种木耳片的制备工艺,具体包括以下步骤:
步骤1、将黑木耳去除杂质后,按重量份称取各原料,然后将木香、香附、干姜、决明子、黄芪混合均匀后,按料液体积比1:8~10,向其中加入水,煎煮提取30min,提取2次,合并2次的提取液后,减压浓缩得中药浸膏;
步骤2、将黑木耳用水浸泡4~5h、洗净后用沸水煮熟,捞出,控去多余水分后,打磨成浆,过200目筛后,得木耳浆;
步骤3、向步骤2所制得的木耳浆中加入步骤1制得的中药浸膏以及松花活性肽,搅拌均匀后,加入粘合剂,继续搅拌至混合均匀,制成软材,然后经湿法制粒、干燥、整粒、压片,即得木耳片。
与现有技术相比,本发明的优点为:
本发明胃蛋白酶采用的pH为4.2,碱性蛋白酶采用的pH为8.0,均非其最适pH,是为了降低酶解的速率,延长酶解时间,从而容易操作,否则酶解速度太快来不及终止反应,使得酶解程度过高,导致得到的3~5kDa的松花活性肽含量减少。
本发明以黑木耳和松花活性肽为减肥主要成分,以木香、香附、干姜、决明子和黄芪为辅,共同起到减肥瘦身的目的;其中,松花活性肽能够通过抑制胰脂肪酶的活性降低脂肪的吸收以达到减肥的目的,木耳片一方面经过胃时吸水膨胀,体积扩大,增加胃的饱腹感,从根本上解决了饥饿想吃东西的情况,另一方面,木耳中的纤维素能够吸收油脂,促进肠胃蠕动,从而达到清理肠壁垃圾,通便减肥的作用;而木香、香附理气健胃,干姜温热健胃,决明子降脂、黄芪补气避免因体重减轻过快带来的元气损伤。
本发明配伍科学,天然安全,无副作用,各组分之间协同作用,功效相辅相成,共同起到减肥瘦身的目的。
具体实施方式
以下结合实施例对本发明进行进一步详细的叙述。
碱性蛋白酶采用Alcalase 2.4L碱性蛋白酶;
胃蛋白酶:上海歆睿生物科技有限公司;
松花分离蛋白:取松花粉按料液质量体积比1g:15~18mL向松花粉中加入去离子水,超声于500~1000W的功率下超声20min,然后用氢氧化钠溶液调pH至10.0,45摄氏度水浴提取50min,3500r/min离心10min,取上清,用盐酸调pH至4.17,静置3h,3500r/min离心15min,取沉淀,冷冻干燥,得松花分离蛋白。
实施例1~6
一种松花活性肽,由松花分离蛋白依次经胃蛋白酶和碱性蛋白酶水解所得,具体步骤如下:
步骤一:酶解:
步骤A:首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用盐酸调整底物溶液的pH为4.2,并加热至37摄氏度后,以底物计向底物溶液中加入1100U/g的胃蛋白酶,于37摄氏度PH4.2的条件下酶解15min,然后采用氢氧化钠调整底物溶液的pH为8.0,并升温至54摄氏度后,以底物计向其中加入2606U/g的碱性蛋白酶,于54摄氏度、pH8.0的条件下酶解30min,然后沸水浴中灭酶15min;得酶解液A;
步骤B:胃蛋白酶的酶解时间为45min,碱性蛋白酶的酶解时间为75min,其余与步骤A相同,得酶解液B;
步骤C:胃蛋白酶的酶解时间为75min,碱性蛋白酶的酶解时间为120min,其余与步骤A相同,得酶解液C;
步骤D:将酶解液A、酶解液B、酶解液C混合,得酶解液;
步骤二:超滤分离:将步骤一制得的酶解液采用分子量为9kDa、7kDa、5kDa、3kDa、1kDa的超滤膜盒依次对酶解液进行分离,分别收集分子量小于1kDa、1~3kDa、3~5kDa、5~7kDa、7~9大于9kDa范围内的各组分溶液;
步骤三:固液分离:分别将步骤二所收集的各组分溶液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
实施例1~6仅收集的松花活性肽分子片段不同,其余均相同;
其中,实施例1为:收集小于1kDa的松花活性肽;
实施例2为:收集1~3kDa的松花活性肽;
实施例3为:收集3~5kDa的松花活性肽;
实施例4为:收集5~7kDa的松花活性肽;
实施例5为:收集7~9kDa的松花活性肽;
实施例6为:收集大于9kDa的松花活性肽。
实施例7
一种松花活性肽,由松花分离蛋白经胃蛋白酶水解所得,具体步骤如下:
步骤一:酶解:
首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用盐酸调整底物溶液的pH为4.2,并加热至37摄氏度后,以底物计向底物溶液中加入1100U/g的胃蛋白酶,于37摄氏度PH4.2的条件下酶解120min;得酶解液;
步骤二:超滤分离:将步骤一制得的酶解液采用分子量为5kDa、3kDa的超滤膜盒依次对酶解液进行分离,收集分子量在3~5kDa范围内的组分溶液;
步骤三:固液分离:将步骤二所收集的分子量在3~5kDa范围内的组分溶液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
实施例8
一种松花活性肽,由松花分离蛋白经碱性蛋白酶水解所得,具体步骤如下:
步骤一:酶解:
首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用氢氧化钠调整底物溶液的pH为8.0,并升温至54摄氏度后,以底物计向其中加入2606U/g的碱性蛋白酶,于54摄氏度、pH8.0的条件下酶解120min,然后沸水浴中灭酶15min;得酶解液;
步骤二:超滤分离:将步骤一制得的酶解液采用分子量为5kDa、3kDa的超滤膜盒依次对酶解液进行分离,收集分子量在3~5kDa范围内的组分溶液;
步骤三:固液分离:将步骤二所收集的分子量在3~5kDa范围内的组分溶液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
实施例9
一种松花活性肽,由松花分离蛋白经中性蛋白酶水解所得,具体步骤如下:
步骤一:酶解:
首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用氢氧化钠调整底物溶液的pH为7.0,并升温至37摄氏度后,以底物计向其中加入1800U/g的中性蛋白酶,于37摄氏度、pH7.0的条件下酶解70min,然后沸水浴中灭酶15min;得酶解液;
步骤二:超滤分离:将步骤一制得的酶解液采用分子量为5kDa、3kDa的超滤膜盒依次对酶解液进行分离,收集分子量在3~5kDa范围内的组分溶液;
步骤三:固液分离:将步骤二所收集的分子量在3~5kDa范围内的组分溶液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
实施例10~14
一种松花活性肽,由松花分离蛋白依次经胃蛋白酶和碱性蛋白酶水解所得,具体步骤如下:
步骤一:酶解:
首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用盐酸调整底物溶液的pH为4.2,并加热至37摄氏度后,以底物计向底物溶液中加入1100U/g的胃蛋白酶,于37摄氏度PH4.2的条件下酶解30~60min,然后采用氢氧化钠调整底物溶液的pH为8.0,并升温至54摄氏度后,以底物计向其中加入2606U/g的碱性蛋白酶,于54摄氏度、pH8.0的条件下酶解60~90min,然后沸水浴中灭酶15min;得酶解液;
步骤二:固液分离
将步骤一所得的酶解液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
实施例10~14中仅胃蛋白酶和碱性蛋白酶的酶解时间不同,其余均相同;
实施例10~14中仅胃蛋白酶和碱性蛋白酶的酶解时间,见下表1;
表1
实施例15
一种松花活性肽,由松花分离蛋白依次经胃蛋白酶和碱性蛋白酶水解所得,具体步骤如下:
步骤一:酶解:
首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用盐酸调整底物溶液的pH为4.2,并加热至37摄氏度后,以底物计向底物溶液中加入1100U/g的胃蛋白酶,于37摄氏度PH4.2的条件下酶解45min,然后采用氢氧化钠调整底物溶液的pH为8.0,并升温至54摄氏度后,以底物计向其中加入2606U/g的碱性蛋白酶,于54摄氏度、pH8.0的条件下酶解75min,然后沸水浴中灭酶15min;得酶解液;
步骤二:超滤分离
将步骤一制得的酶解液采用分子量为5kDa、3kDa的超滤膜盒依次对酶解液进行分离,收集分子量在3~5kDa范围内的组分溶液;
步骤三:固液分离
将步骤二所收集分子量在3~5kDa范围内的组分溶液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
实施例16
一种木耳片,包括以下重量份的各原料:
黑木耳80份;木香4份;香附4份;干姜4份;决明子4份;黄芪4份;实施例12制得的松花活性肽6份;
其制备方法为:
步骤1、将黑木耳去除杂质后,按重量份称取各原料,然后将木香、香附、干姜、决明子、黄芪混合均匀后,按料液体积比1:8~10,向其中加入水,煎煮提取30min,提取2次,合并2次的提取液后,减压浓缩得中药浸膏;
步骤2、将黑木耳用水浸泡4~5h、洗净后用沸水煮熟,捞出,控去多余水分后,打磨成浆,过200目筛后,得木耳浆;
步骤3、向步骤2所制得的木耳浆中加入步骤1制得的中药浸膏以及松花活性肽,搅拌均匀后,加入粘合剂,混合均匀,制成软材,然后经湿法制粒、干燥、整粒后,压片,即得木耳片。
实施例17
采用实施例15制得的松花活性肽4份;其余均同实施例16。
实施例18
一种木耳片,包括以下重量份的各原料:
黑木耳80份;木香4份;香附4份;干姜4份;决明子4份;黄芪4份;
其制备方法为:
步骤1、将黑木耳去除杂质后,按重量份称取各原料,然后将木香、香附、干姜、决明子、黄芪混合均匀后,按料液体积比1:8~10,向其中加入水,煎煮提取30min,提取2次,合并2次的提取液后,减压浓缩得中药浸膏;
步骤2、将黑木耳用水浸泡4~5h、洗净后用沸水煮熟,捞出,控去多余水分后,打磨成浆,过200目筛后,得木耳浆;
步骤3、向步骤2所制得的木耳浆中加入步骤1制得的中药浸膏,搅拌均匀后,加入粘合剂,继续搅拌至混合均匀,制成软材,然后经湿法制粒、干燥、整粒、压片,即得木耳片。
效果例1:松花活性肽对脂肪酶的抑制作用
一、试验方法
1、药品:
实施例1~15制得的松花活性肽;奥利司他
2、分组情况:
试验一组:采用实施例1制得的松花活性肽;
试验二组:采用实施例2制得的松花活性肽;
试验三组:采用实施例3制得的松花活性肽;
试验四组:采用实施例4制得的松花活性肽;
试验五组:采用实施例5制得的松花活性肽;
试验六组:采用实施例6制得的松花活性肽;
试验七组:采用实施例7制得的松花活性肽;
试验八组:采用实施例8制得的松花活性肽;
试验九组:采用实施例9制得的松花活性肽;
试验十组:采用实施例10制得的松花活性肽;
试验十一组:采用实施例11制得的松花活性肽;
试验十二组:采用实施例12制得的松花活性肽;
试验十三组:采用实施例13制得的松花活性肽;
试验十四组:采用实施例14制得的松花活性肽;
试验十五组:采用实施例15制得的松花活性肽;
药物对照组:奥利司他;
空白对照组:不采用任何药物。
3、试验方法
(1)试剂配制
奥利司他母液配置:取奥利司他溶于二甲基亚砜中,配置成15mg/mL的奥利司他母液;临用前用去离子水稀释3倍使用;
待测样品溶液的配制:按照体积比为1:2配置二甲亚砜和去离子水,形成二甲亚砜水溶液,然后向二甲亚砜水溶液加入待测样品,配制成浓度均为5mg/ml的待测样品溶液,临用前配制;
缓冲液配制:50mM Tris-HCl溶液,pH值为8.8。
酶溶液配制:用缓冲液配制1.2mg/mL酶,混匀,5000rpm离心5分钟,取上清,分装,-70℃保存,临用前采用缓冲液将其稀释120倍使用。
底物溶液配制:称取0.302g pNPP,加入32ml异丙醇,超生乳化,即为25mMpNPP,分装,4℃保存,临用前采用缓冲液稀释50倍使用;
(2)脂肪酶抑制剂活性测定
取96孔细胞培养板,按照表2中不同的分组分别加入缓冲液、抑制剂和脂肪酶,37℃孵育10分钟。脂肪酶和抑制剂预孵育10分钟后,每孔加入100μl底物,37℃反应60分钟。在酶标仪OD405nm处测量各孔的吸光值;
表2为脂肪酶抑制剂筛选反应体系(200μL)
缓冲溶液 | 抑制剂 | 脂肪酶 | 底物/μL | |
A | 50 | 0 | 50 | 100 |
a | 100 | 0 | 0 | 100 |
B | 30 | 20 | 50 | 100 |
b | 80 | 20 | 0 | 100 |
A:为未加抑制剂的酶活;a:为未加抑制剂的空白对照(未加酶);
B:为加抑制剂的酶活;b:为加抑制剂的空白对照(未加酶)。
2.结果处理及分析
脂肪酶抑制率的计算公式:脂肪酶抑制率%=[1-(B-b)/(A-a)]×100;
各试验组和对照组对脂肪酶抑制作用的测试结果,见表3;
表3各试验组和对照组对脂肪酶抑制作用的测试结果
由表中数据可知:从试验一组至试验六组的对比可知:酶解后的片段大小对制得的松花活性肽的脂肪酶抑制作用影响显著,以3~5kDa松花活性肽效果最好,1~3kDa松花活性肽效果次之,由试验七组至试验九组与试验十二组的对比可知:酶的种类对制得的松花活性肽的脂肪酶抑制作用影响显著;当采用胃蛋白酶和碱性蛋白酶2种酶依次酶解并收集的3~5kDa的活性肽其对脂肪酶抑制作用的抑制作用最佳,随着活性肽分子量的增大或减小效果降低,且采用其他没进行酶解所得活性肽对脂肪酶无抑制作用。从试验十组到试验十四组的数据对比可知:酶解时间对松花分离蛋白的水解程度影响巨大,当采用胃蛋白酶酶解45min、碱性蛋白酶酶解75min时,由于所得活性肽中的3~5kDa的活性肽含量最多,因此其对脂肪酶的抑制作用最佳。实施例三组和试验十五组与药物对照组相比可知:本发明松花活性肽对胰脂肪酶活性的抑制作用与奥利司他对胰脂肪酶活性的抑制作用相当或更优。
效果例2实施例10~14中制得的酶解液中的分子量分布情况
使用TSK GEL G3000PWXL色谱柱,通过高效液相色谱测定松花肽的分子量分布。检测条件:以体积比1:1的乙腈与0.2%三氟乙酸(TFA)混合溶液为流动相,按0.5mL/min的流速过柱,紫外检测波长为225nm。取牛血清蛋白、VB12、及胶原蛋白样品各1mg,分别溶于1mL的纯水中,用0.45μm微孔滤膜过滤后进样。HPLC结果通过GPC软件进行分子量分布分析,结果见表4。
表4酶解液中的分子量分布情况
由表中数据可知,实施例12中的酶解液中3~5kDa以及1~5kDa的松花活性肽均为最多。
效果例4木耳片的减肥临床应用效果
1、实验对象与方法
1.1实验对象
本实验全部受试者在实验前分别进行体质指数评估均为肥胖人群,150例受试者中男75例,女75例;年龄在18-45岁之间,平均年龄(30.2±10.7)岁。
1.2实验方法
分组:180名受试者随机分为6组,实验一组(N=30)、实验二组(N=30)、实验三组(N=30)、实验四组(N=30)、药物对照组(N=30)、阴性对照组(N=30);
分组情况:
实验一组:服用本发明实施例16中制备的木耳片,10片/天,每片重0.7g,餐中服用;
实验二组:服用本发明实施例17中制备的木耳片,10片/天;每片重0.7g,餐中服用;
实验三组:服用本发明实施例18中制备的木耳片,10片/天;每片重0.7g,餐中服用;
实验四组:服用本发明实施例12中制备的松花活性肽,0.46g/天;分三次餐中服用;
药物对照组:服用奥利司他,0.36g/天;餐中服用;
阴性对照组:服用安慰剂,10片/天;每片重0.7g,餐中服用;
每组按照上述方法连续服用8周。整个实验期间,不控制饮食,不刻意增加运动,并禁服其他减肥食品和药品。
1.3测试指标
1.3.1人体成分测试:实验前和实验后每周采用DX200超强型体成分测试仪测试受试者的体重,体脂百分比。
1.3.2记录各组中不良反应发生的人数;不良反应包括:大便次数增多(每天大于等于3次)、稀便、腹痛、恶心、呕吐及油性呃逆、上呼吸道和下呼吸道感染、头痛、疲劳、焦虑、泌尿系感染、月经失调等反应。
1.4数据统计
所得数据用Excel处理,采用单盲法和t检验对测试数据进行统计学分析,用mean±SD表示。
2、实验结果与分析
2.1人体成分分析结果
2.1.1实验前、服药8周后受试者体重及体脂检测结果,见表5;
表5服药8周后受试者体重及体脂检测结果
由表中数据可知:含有松花活性肽的试验一组、试验二组以及试验四组效果显著,而缺少松花活性肽的试验三组效果较差,但仍旧优于阴性对照组试验三组与药物对照组效果差异不显著,但不良反应显著优于药物对照组。
以上所述实施方式仅为本发明的优选实施例,而并非本发明可行实施的穷举。对于本领域一般技术人员而言,在不背离本发明原理和精神的前提下对其所作出的任何显而易见的改动,都应当被认为包含在本发明的权利要求保护范围之内。
Claims (8)
1.一种松花活性肽,其特征在于,由松花分离蛋白依次经胃蛋白酶和Alcalase 2.4L碱性蛋白酶水解所得,具体步骤如下:
步骤一:酶解:首先,向松花分离蛋白中加入水,配制成质量浓度为2g/100mL的松花蛋白溶液作为底物;采用盐酸调整底物溶液的pH为4.2,并加热至37摄氏度后,以底物计向底物溶液中加入1100U/g的胃蛋白酶,于37摄氏度PH4.2的条件下酶解30~60min,然后采用氢氧化钠调整底物溶液的pH为8.0,并升温至54摄氏度后,以底物计向其中加入2606U/g的碱性蛋白酶,于54摄氏度、pH8.0的条件下酶解60~90min,然后沸水浴中灭酶15min;得酶解液;
步骤二:固液分离:将步骤一所得的酶解液于10000r/min的转速下离心,收集沉淀,冷冻干燥,即得。
2.根据权利要求1所述的松花活性肽,其特征在于,步骤二中,在离心前还包括采用分子量为5kDa和3KDa的超滤膜盒依次对酶解液进行分离,收集分子量在3~5kDa范围内的组分。
3.一种如权利要求1~2任一项所述的松花活性肽作为减肥活性成分在制备减肥药物中的应用。
4.一种包含权利要求1~2任一项所述松花活性肽的组合物,其特征在于,包括以下重量份的各原料:木香4份;香附4份;干姜4份;决明子4份;黄芪4份;权利要求1~2任一项所述松花活性肽2~9份。
5.根据权利要求4所述的组合物,其特征在于,所述组合物还包括药学上可接受的载体。
6.一种包含如权利要求4所述组合物的临床制剂,其特征在于,所述制剂为口服剂型,选自汤剂、散剂、胶囊剂、片剂、合剂、糖浆剂、内服膏剂、丸剂或口服液。
7.一种包含根权利要求4所述的组合物的木耳片,其特征在于,按重量份计,还包括黑木耳80份。
8.一种木耳片的制备工艺,其特征在于,具体包括以下步骤:
步骤1、将黑木耳去除杂质后,按重量份称取各原料,然后将木香、香附、干姜、决明子、黄芪混合均匀后,按料液体积比1:8~10,向其中加入水,煎煮提取30min,提取2次,合并2次的提取液后,减压浓缩得中药浸膏;
步骤2、将黑木耳用水浸泡4~5h、洗净后用沸水煮熟,捞出,控去多余水分后,打磨成浆,过200目筛后,得木耳浆;
步骤3、向步骤2所制得的木耳浆中加入步骤1制得的中药浸膏以及松花活性肽,搅拌均匀后,加入粘合剂,继续搅拌至混合均匀,制成软材,然后经湿法制粒、干燥、整粒、压片,即得木耳片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910168836.5A CN109694895A (zh) | 2019-03-06 | 2019-03-06 | 松花活性肽、包含其的组合物、木耳片及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910168836.5A CN109694895A (zh) | 2019-03-06 | 2019-03-06 | 松花活性肽、包含其的组合物、木耳片及其制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109694895A true CN109694895A (zh) | 2019-04-30 |
Family
ID=66233819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910168836.5A Pending CN109694895A (zh) | 2019-03-06 | 2019-03-06 | 松花活性肽、包含其的组合物、木耳片及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109694895A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101100691A (zh) * | 2007-07-13 | 2008-01-09 | 承德畅达天然营养品有限公司 | 用酶从油松花粉中提取小肽的方法 |
CN101455739A (zh) * | 2007-12-14 | 2009-06-17 | 北京琥珀光华医药科技开发有限公司 | 一种治疗高脂血症的纯中药制剂 |
CN102659917A (zh) * | 2012-05-24 | 2012-09-12 | 烟台新时代健康产业有限公司 | 一种从松花粉中分离制备粗蛋白及酶解肽类的方法 |
CN104546980A (zh) * | 2013-10-21 | 2015-04-29 | 中国科学院大连化学物理研究所 | 一种蜂花粉提取物及其制备和应用 |
CN104593461A (zh) * | 2014-12-29 | 2015-05-06 | 唯美度科技(北京)有限公司 | 一种低分子量蜂花粉蛋白肽及其制备方法 |
CN106539069A (zh) * | 2016-09-24 | 2017-03-29 | 哈尔滨工业大学 | 一种抗疲劳抗辐射复合能量棒的制作方法 |
CN107574215A (zh) * | 2017-07-25 | 2018-01-12 | 赵德润 | 一种松花粉活性肽的制备方法 |
CN107988299A (zh) * | 2017-12-01 | 2018-05-04 | 烟台新时代健康产业有限公司 | 一种利用松花粉粕制备抗氧化松花粉肽的方法 |
-
2019
- 2019-03-06 CN CN201910168836.5A patent/CN109694895A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101100691A (zh) * | 2007-07-13 | 2008-01-09 | 承德畅达天然营养品有限公司 | 用酶从油松花粉中提取小肽的方法 |
CN101455739A (zh) * | 2007-12-14 | 2009-06-17 | 北京琥珀光华医药科技开发有限公司 | 一种治疗高脂血症的纯中药制剂 |
CN102659917A (zh) * | 2012-05-24 | 2012-09-12 | 烟台新时代健康产业有限公司 | 一种从松花粉中分离制备粗蛋白及酶解肽类的方法 |
CN104546980A (zh) * | 2013-10-21 | 2015-04-29 | 中国科学院大连化学物理研究所 | 一种蜂花粉提取物及其制备和应用 |
CN104593461A (zh) * | 2014-12-29 | 2015-05-06 | 唯美度科技(北京)有限公司 | 一种低分子量蜂花粉蛋白肽及其制备方法 |
CN106539069A (zh) * | 2016-09-24 | 2017-03-29 | 哈尔滨工业大学 | 一种抗疲劳抗辐射复合能量棒的制作方法 |
CN107574215A (zh) * | 2017-07-25 | 2018-01-12 | 赵德润 | 一种松花粉活性肽的制备方法 |
CN107988299A (zh) * | 2017-12-01 | 2018-05-04 | 烟台新时代健康产业有限公司 | 一种利用松花粉粕制备抗氧化松花粉肽的方法 |
Non-Patent Citations (5)
Title |
---|
"悬浮剂XF3在果蔬汁饮料中的应用 ", 《农产品加工》 * |
支崇远等: "四种松花粉营养成分比较研究 ", 《中国自然医学杂志》 * |
支崇远等: "四种松花粉营养成分比较研究", 《中国自然医学杂志》 * |
李守汉等: "破壁松花粉对运动大鼠免疫功能及运动能力的影响 ", 《营养学报》 * |
李守汉等: "破壁松花粉对运动大鼠免疫功能及运动能力的影响", 《营养学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105753935B (zh) | 一种葵花盘小分子肽及制备方法和医用用途 | |
CN103355556A (zh) | 一种玉米型断奶仔猪配合饲料及其制备方法 | |
CN109758571A (zh) | 一种促进尿酸代谢、改善痛风、保护关节的组合物及其制备方法 | |
CN108339112A (zh) | 一种用于促进创伤愈合、褥疮修复、术后应激性溃疡愈合的营养组合物 | |
WO2012034498A1 (zh) | 一种增强机体免疫力并能控制糖尿病的产品 | |
CN109939143A (zh) | 一种用于降血糖控制并发症的中药组合物及其制备方法 | |
CN109123686A (zh) | 一种具有保健功能的火麻籽粉高蛋白素肉及其制备方法 | |
CN100444746C (zh) | 一种高寒山区作物精制健康食品及其加工工艺 | |
CN108524673A (zh) | 一种中药组合物及其应用 | |
CN109400750B (zh) | 一种具有降尿酸作用的药物组合物 | |
CN101946895B (zh) | 一种以泥鳅为主料的功能食品及其制备方法 | |
WO2015190872A1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
US20070166405A1 (en) | Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases | |
CN105943958A (zh) | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 | |
CN109718273A (zh) | 紫苏叶提取物在预防或治疗骨性关节炎中的应用 | |
CN108837121A (zh) | 一种治疗高尿酸的中药组合物及其制备方法 | |
CN1839702A (zh) | 复方绞股兰活心健脑辅疗茶及其制备方法 | |
CN111802646A (zh) | 一种阻止肌肉衰减的营养组合物及其制备方法 | |
CN101757083B (zh) | 含有木香烯内酯的治疗胃肠疾病中药组合物及其制备方法 | |
CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN106070783A (zh) | 一种薏米祛湿茶的生产工艺 | |
CN110559389A (zh) | 一种用于高尿酸、痛风和风湿病的中药酒及制备方法 | |
CN105995980B (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
CN102048841A (zh) | 一种具有催乳作用的中药组合物及其制备工艺 | |
CN109694895A (zh) | 松花活性肽、包含其的组合物、木耳片及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190430 |
|
RJ01 | Rejection of invention patent application after publication |